相似文献
1
The differential ability of human IgG1 and IgG4 to activate complement is determined by the COOH-terminal sequence of the CH2 domain.
J Exp Med. 1991 Apr 1;173(4):1025-8. doi: 10.1084/jem.173.4.1025.
2
Amino acid differences in the N-terminus of C(H)2 influence the relative abilities of IgG2 and IgG3 to activate complement.
Mol Immunol. 1997 Oct;34(14):1019-29. doi: 10.1016/s0161-5890(97)00112-0.
3
Residue at position 331 in the IgG1 and IgG4 CH2 domains contributes to their differential ability to bind and activate complement.
J Biol Chem. 1994 Feb 4;269(5):3469-74.
4
The N-terminal end of the CH2 domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc gamma RI and Fc gamma RIII binding.
Immunology. 1995 Oct;86(2):319-24.
5
IgG2 Fc structure and the dynamic features of the IgG CH2-CH3 interface.
Mol Immunol. 2013 Nov;56(1-2):131-9. doi: 10.1016/j.molimm.2013.03.018. Epub 2013 Apr 28.
6
CH2 Domain of Mouse IgG3 Governs Antibody Oligomerization, Increases Functional Affinity to Multivalent Antigens and Enhances Hemagglutination.
Front Immunol. 2018 May 23;9:1096. doi: 10.3389/fimmu.2018.01096. eCollection 2018.
7
Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life.
Cancer Res. 1998 Sep 1;58(17):3905-8.
8
Chimeric mouse human IgG3 antibodies with an IgG4-like hinge region induce complement-mediated lysis more efficiently than IgG3 with normal hinge.
Eur J Immunol. 1991 Oct;21(10):2379-84. doi: 10.1002/eji.1830211013.
9
The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region.
J Exp Med. 1991 Jun 1;173(6):1483-91. doi: 10.1084/jem.173.6.1483.
10
Mapping rheumatoid factor binding sites using genetically engineered, chimeric IgG antibodies.
DNA Cell Biol. 1992 Apr;11(3):245-52. doi: 10.1089/dna.1992.11.245.
引用本文的文献
1
Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement system.
Commun Biol. 2024 Jul 17;7(1):871. doi: 10.1038/s42003-024-06556-0.
2
Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma.
Cancers (Basel). 2023 Mar 17;15(6):1816. doi: 10.3390/cancers15061816.
3
Factors affecting IgG4-mediated complement activation.
Front Immunol. 2023 Jan 26;14:1087532. doi: 10.3389/fimmu.2023.1087532. eCollection 2023.
4
Kidney diseases.
Immunol Rev. 2023 Jan;313(1):239-261. doi: 10.1111/imr.13167. Epub 2022 Nov 12.
5
The Alternative Pathway Is Necessary and Sufficient for Complement Activation by Anti-THSD7A Autoantibodies, Which Are Predominantly IgG4 in Membranous Nephropathy.
Front Immunol. 2022 Jul 7;13:952235. doi: 10.3389/fimmu.2022.952235. eCollection 2022.
6
New Insights into the Treatment of Glomerular Diseases: When Mechanisms Become Vivid.
Int J Mol Sci. 2022 Mar 24;23(7):3525. doi: 10.3390/ijms23073525.
7
Host receptor-targeted therapeutic approach to counter pathogenic New World mammarenavirus infections.
Nat Commun. 2022 Jan 28;13(1):558. doi: 10.1038/s41467-021-27949-3.
8
Generation of a Universal Human Complement Source by Large-Scale Depletion of IgG and IgM from Pooled Human Plasma.
Methods Mol Biol. 2022;2414:341-362. doi: 10.1007/978-1-0716-1900-1_18.
9
Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV Human Primary B-cells.
Mol Cancer Ther. 2021 Sep;20(9):1592-1602. doi: 10.1158/1535-7163.MCT-21-0074. Epub 2021 Jun 22.
10
Upregulating hsa-miR-128a Increased the Effects of Pembrolizumab on Laryngeal Cancer Cells via the p53 Pathway.
Biomed Res Int. 2021 Mar 18;2021:2342784. doi: 10.1155/2021/2342784. eCollection 2021.
本文引用的文献
1
2
Expression of biological effector functions by immunoglobulin G molecules lacking the hinge region.
Proc Natl Acad Sci U S A. 1981 Jan;78(1):524-8. doi: 10.1073/pnas.78.1.524.
3
Preparation and biologic characterization of fragments containing dimeric and monomeric C gamma 2 domain of rabbit IgG.
Mol Immunol. 1985 Jul;22(7):811-9. doi: 10.1016/0161-5890(85)90147-6.
4
Effector functions of a monoclonal aglycosylated mouse IgG2a: binding and activation of complement component C1 and interaction with human monocyte Fc receptor.
Mol Immunol. 1985 Apr;22(4):407-15. doi: 10.1016/0161-5890(85)90125-7.
5
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies.
J Exp Med. 1987 Nov 1;166(5):1351-61. doi: 10.1084/jem.166.5.1351.
6
The binding site for C1q on IgG.
Nature. 1988 Apr 21;332(6166):738-40. doi: 10.1038/332738a0.
7
Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.
EMBO J. 1988 Jul;7(7):1989-94. doi: 10.1002/j.1460-2075.1988.tb03037.x.
8
Production and properties of chimeric antibody molecules.
Methods Enzymol. 1989;178:459-76. doi: 10.1016/0076-6879(89)78034-4.
9
Studies of aglycosylated chimeric mouse-human IgG. Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region.
J Immunol. 1989 Oct 15;143(8):2595-601.
10
Role for the third constant domain of the IgG H chain in activation of complement in the presence of C1 inhibitor.
J Immunol. 1989 Jan 1;142(1):195-201.
Zotero 插件